Sabzevari Helen — SEC Form 4 filings
SEC reporting owner CIK 1724195. 15 Form 4 filings on record with FilingPulse; latest filed 2026-08-25.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-04-05 to 2026-08-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 466,086 shares, $2,562,794 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 29.
- Largest priced transaction: sale of 346,836 shares @ $5.89 ($2,042,864) in PRECIGEN, INC., filed 2026-07-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| PRECIGEN, INC. (PGEN) | President and CEO | 14 | — | 2 legs · 466,086 sh · $2,562,794 | 26 |
| Kinnate Biopharma Inc. (KNTE) | Director | 1 | — | — | 3 |
Form 4 filings — Sabzevari Helen
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-25 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 20,833 · Tax withholding (F): 10,184 @ $7.20 · Option exercise (M): 20,833 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 346,836 @ $2.33 · Sale (S): 346,836 @ $5.89 · Option exercise (M): 346,836 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | PRECIGEN, INC. (PGEN) | Sale (S): 119,250 @ $4.36 | EDGAR |
| 2026-05-27 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 250,000 · Option exercise (M): 250,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 1,366,000 (derivative) @ $0 · Grant/award (A): 410,000 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 321,100 · Grant/award (A): 321,100 (derivative) @ $0 · Option exercise (M): 321,100 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 825,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 1,079,137 · Tax withholding (F): 521,224 @ $1.45 · Option exercise (M): 1,079,137 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 1,079,137 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 825,000 @ $0 · Tax withholding (F): 286,967 @ $1.30 | EDGAR |
| 2024-05-31 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 1,803,000 (derivative) @ $0 | EDGAR |
| 2024-04-09 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 1,071,429 · Tax withholding (F): 410,357 @ $1.40 · Grant/award (A): 1,071,429 (derivative) @ $0 · Option exercise (M): 1,071,429 (derivative) @ $0 | EDGAR |
| 2024-04-05 | 4 | Kinnate Biopharma Inc. (KNTE) | Disposition to issuer (D): 40,501 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 20,250 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1724195 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →